GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Glaukos Corp (NYSE:GKOS) » Definitions » ROE %

Glaukos (Glaukos) ROE % : -31.32% (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Glaukos ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Glaukos's annualized net income for the quarter that ended in Dec. 2023 was $-147.1 Mil. Glaukos's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $469.7 Mil. Therefore, Glaukos's annualized ROE % for the quarter that ended in Dec. 2023 was -31.32%.

The historical rank and industry rank for Glaukos's ROE % or its related term are showing as below:

GKOS' s ROE % Range Over the Past 10 Years
Min: -27.3   Med: -8.11   Max: 4.26
Current: -27.3

During the past 11 years, Glaukos's highest ROE % was 4.26%. The lowest was -27.30%. And the median was -8.11%.

GKOS's ROE % is ranked worse than
68.43% of 811 companies
in the Medical Devices & Instruments industry
Industry Median: 0.31 vs GKOS: -27.30

Glaukos ROE % Historical Data

The historical data trend for Glaukos's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Glaukos ROE % Chart

Glaukos Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.64 -17.95 -7.91 -17.76 -27.16

Glaukos Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -23.33 -26.67 -26.32 -25.20 -31.32

Competitive Comparison of Glaukos's ROE %

For the Medical Devices subindustry, Glaukos's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Glaukos's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Glaukos's ROE % distribution charts can be found below:

* The bar in red indicates where Glaukos's ROE % falls into.



Glaukos ROE % Calculation

Glaukos's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-134.661/( (530.005+461.766)/ 2 )
=-134.661/495.8855
=-27.16 %

Glaukos's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-147.116/( (477.659+461.766)/ 2 )
=-147.116/469.7125
=-31.32 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Glaukos  (NYSE:GKOS) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-147.116/469.7125
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-147.116 / 329.46)*(329.46 / 944.524)*(944.524 / 469.7125)
=Net Margin %*Asset Turnover*Equity Multiplier
=-44.65 %*0.3488*2.0109
=ROA %*Equity Multiplier
=-15.57 %*2.0109
=-31.32 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-147.116/469.7125
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-147.116 / -146.872) * (-146.872 / -154.488) * (-154.488 / 329.46) * (329.46 / 944.524) * (944.524 / 469.7125)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0017 * 0.9507 * -46.89 % * 0.3488 * 2.0109
=-31.32 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Glaukos ROE % Related Terms

Thank you for viewing the detailed overview of Glaukos's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Glaukos (Glaukos) Business Description

Traded in Other Exchanges
Address
One Glaukos Way, Aliso Viejo, CA, USA, 92656
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
Executives
Alex R. Thurman officer: SVP & Chief Financial Officer C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Joseph E Gilliam officer: CFO, SVP Corporate Development C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92677
Thomas William Burns director, 10 percent owner, officer: Chief Executive Officer C/O GLAUKOS CORPORATION,, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Marc Stapley director 9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Gilbert H Kliman director C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022
Tomas Navratil officer: Chief Development Officer C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Leana Wen director C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Denice Torres director 3 RABBIT RUN DRIVE, NEW HOPE PA 18938
Chris M. Calcaterra officer: Chief Commercial Officer C/O GLAUKOS CORPORATION, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Link William J Phd director, 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Jonathan Silverstein director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Advisors Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Richard L Harrison officer: Treasurer, CFO & Secretary 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Samuel D Isaly director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Iii Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022